Sheep anti Human C1q antibody
recognizes human C1q, a sub-component of complement C1. C1q associates with complement components C1r and C1s, which are required for the progression of the proteolytic complement cascade. Deficiency of C1q has been associated with lupus erythematosus and glomerulonephritis (Troedson et al. 2013
Sheep anti human C1q antibody may cross react with C1q in other species.
- Target Species
- Product Form
- Purified IgG conjugated to Horseradish Peroxidase (HRP) - liquid
- Antiserum Preparation
- Antisera to human C1q were raised by repeated immunisation of sheep with highly purified antigen. Purified IgG was prepared from whole serum by protein G affinity chromatography.
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
HRP stabiliser (BUF052A)
- Human C1q.
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml
- Store at +4oC. DO NOT FREEZE.
This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.
- 12 months from date of despatch
- Entrez Gene
- GO Terms
complement component C1 complex
complement activation, classical pathway
innate immune response
negative regulation of granulocyte differentiation
negative regulation of macrophage differentiation
- For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of C1q antibody
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
Application Based External Images
Product Specific References
References for C1q antibody
Nascimento, E.J. et al. (2009) Alternative complement pathway deregulation is correlated with dengue severity.
PLoS One. 4:e6782
Lewis, M.J. et al. (2007) The different effector function capabilities of the seven equine IgG subclasses have implications for vaccine strategies.
Mol Immunol. 45: 818-27.
Jacobs, B.C. et al. (2003) Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding.
Brain. 126: 2220-34.
Arduin, E. et al. (2015) Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.
Mol Immunol. 63 (2): 456-63.
Kao, D. et al. (2015) A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors.
Cell Rep. 13 (11): 2376-85.
Gearing, D.P. et al. (2016) In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats.
J Vet Intern Med. 30 (4): 1129-37.